Pradama
Stage
Series B | AliveTotal Raised
$700KValuation
$0000Last Raised
$700K | 15 yrs agoAbout Pradama
Pradama, Inc. is a pharmaceutical company focused on the development and commercialization of products to treat bone diseases and disorders. Pradama is developing compounds that target bone with the initial two products designed for osteoporosis treatment and an antineoplastic compound for the treatment of bone metastases.
Missing: Pradama's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Pradama's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Pradama
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Pradama is included in 1 Expert Collection, including Biopharma Tech.
Biopharma Tech
5,241 items
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Pradama Frequently Asked Questions (FAQ)
Where is Pradama's headquarters?
Pradama's headquarters is located at 201 East Jefferson Street, Louisville.
What is Pradama's latest funding round?
Pradama's latest funding round is Series B.
How much did Pradama raise?
Pradama raised a total of $700K.
Who are the investors of Pradama?
Investors of Pradama include Triathlon Medical Venture Partners, Kentucky Seed Capital Fund and Commonwealth Seed Capital.
Who are Pradama's competitors?
Competitors of Pradama include Humanetics, Tarsa Therapeutics, Auxilium Pharmaceuticals, Santarus, Aursos and 13 more.
Compare Pradama to Competitors
Humanetics is a clinical-stage pharmaceutical company engaged in developing and commercializing products to enhance human health and wellbeing in markets with urgent and unmet needs. It has a focus on radiation modulators for oncology, medical imaging, and medical countermeasure uses. The company develops BIO 300, a highly selective modulator of inflammation, cell cycle arrest, and DNA damage repair. Humanetics was founded in 1988 and is based in Minneapolis, Minnesota.

Neurelis is a specialty pharmaceutical company that devleops and commercializes product candidates for epilepsy and the broader central nervous system (CNS) market.
Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.
Phylogix is an early-stage pharmaceutical company developing chemoprotectant compounds.
Neuraltus Pharmaceuticals is a privately-held biopharmaceutical company dedicated to developing and commercializing innovative therapeutics that address critical unmet needs for patients and physicians in the treatment of neurodegenerative diseases. The Company is collaborating with global ALS specialists and seeking input from patient advocacy organizations to help inform the clinical development path and better understand the needs of people affected by the disease.
Roxro Pharma is an early-stage specialty pharmaceutical company dedicated to identifying, licensing, and developing compounds in specialized disease areas with significant sales potential, such as pain management. Roxro will pursue product development with the objective of commercializing these products. Niche products will not be developed by major pharmaceutical companies because they will not fuel their growth requirements. Foreign and biotechnology companies with compounds that have a limited sales potential will not be partnered with major pharmaceutical companies. Therefore there are a number of products not being developed even though they are efficacious, safe and satisfy an unmet medical need.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.